Sanofi R&D head bemoans divergence in global drug regulation

March 18, 2015 4:40 PM

16 0

LONDON (Reuters) - The gap between regulatory decisions on new medicines made in different parts of the world is increasing, imposing a high cost on industry and deterring investment, the head of research at France's Sanofi said on Wednesday.

Elias Zerhouni, speaking at a conference in London to mark the 20th anniversary of the European Medicines Agency (EMA), said there was an "urgent" need to harmonize regulations, potentially through discussions at the G8 or G20 groups of nations.

Read more

To category page